Recent Victories

2010

  • Celebrates 20th anniversary year.
  • Successfully advocates at the FDA to deny Genentech accelerated approval for TDM-1 for metastatic breast cancer patients based on one single-armed trial that has not given sufficient information on efficacy and safety. BCA continues to uphold stringent drug approval standards over hasty access without legitimate clinical benefit. BCA will continue to monitor how TDM-1 performs in Phase III trials.
  • Activates over 6,700 people to take action through BCA’s Milking Cancer campaign. Milking Cancer demands that Eli Lilly stop manufacturing rBGH (artificial recombinant bovine growth hormone) because it is linked to breast cancer. Eli Lilly also makes breast cancer “prevention” and treatment drugs.
  • Successfully advocates at the FDA to stop the use of Avastin as treatment for metastatic breast cancer. In 2007, BCA was the only breast cancer organization to put patients first by actively opposing the use of Avastin for metastatic breast cancer because of its failure to improve overall survival or quality of life, its side effects, and high price tag. In 2010, BCA's position was endorsed by a number of breast cancer organizations.
  • Launches “What the Cluck?” an award-winning advocacy campaign that demands an end to Kentucky Fried Chicken and Susan G. Komen for the Cure’s pinkwashing campaign, “Buckets for the Cure.” Over 5,200 take action. The campaign wins a second place Path to Victory Award from Business Ethics Network and is covered by bloggers and national news outlets including NPR, Huffington Post, Fox News, and The Colbert Report.
  • Forms Screening Task Force in response to the U.S. Preventative Services Task Force’s breast cancer screening recommendations released in November 2009. While BCA’s screening policy is hailed as a leader in the field, the task force revised the policy to address the needs of all affected communities.
  • Wins the first round of lawsuits against Myriad Genetics by challenging the company’s patents on breast cancer genes BRCA1 and BRCA2. Patents were ruled invalid by a United States Federal judge on March 29, 2010.

2009

  • General Mills announced that it would remove the cancer-linked synthetic growth hormone, rBGH, from Yoplait Yogurt
  • Dannon followed suit, announcing they will be rBGH-free by 2010.  Together General Mills and Dannon represent two-thirds of the U.S. dairy market
  • Congress funds Comparative Effectiveness Research effort as part of the federal economic stimulus
  • BCA's victorious 2008 Think Before You Pink campaign, "Yoplait: Put a Lid on it" won the first place 2009 BENNY Award from the Business Ethics Network. The annual BENNY Awards recognize outstanding corporate campaign victories.
  • Launched Milking Cancer campaign, demanding that Eli Lilly stop making rBGH, thus removing it from the world market. Thousands take action in the first week.
  • Successfully testified on behalf of patients at the FDA against the approval of Doxil for metastatic breast cancer
  • Joined ACLU in lawsuit against Myriad Genetics for their patents on breast cancer genes BRCA1 and BRCA2

2008

  • Activated 1500 people to take action against pinkwashing just two weeks into our Think Before You Pink campaign
  • Met with Genentech (Avastin) and Amgen (anemia drugs) representatives to air concerns about their products
  • Launched five-year strategic plan—challenging assumptions and inspiring change in breast cancer advocacy
  • Published its 100th edition of the bi-monthly newsletter, The Source
  • Successfully advocated for removal of phthalates in cosmetics made by Secret, Arrid and Christian Dior
  • Think Before You Pink Critical Questions appear in promotional literature and media statements from Komen and the American Cancer Society

2007

  • Initiated First National Breast Cancer Research Summit, a gathering of funders, scientists, and key activists from around the nation
  • Think Before You Pink web site was Yahoo! pick of the month for October
  • Asserted a unique perspective, focusing on cost and effectiveness, in opposition to approval of Avastin as a treatment for breast cancer
  • Successfully argued for cancellation of STELLAR Trial, maintaining that pills for prevention always results in disease substitution
  • Published initial Aromatase Inhibitor Side-effects Survey results

2006

  • Founding member of CHANGE, a coalition of organizations working to create a better system for regulating toxic chemicals in California
  • Fenton Communications featured BCA's Think Before You Pink campaign as a case study in its presentation, “Because It’s Worth It: 10 Ways to Measure the Impact of Your Communications”
  • BAWG, co-founded by BCA, wins "Pioneers of Precaution" award at the First National Conference on the Precautionary Principle in Baltimore, MD

2005

  • BCA’s California Safe Cosmetics Act of 2005 (SB 484) enacted
  • BCA's Think Before You Pink campaign inspired Komen and Breast Cancer Research Foundation to post their own questions consumers should ask before buying pink ribbon products
  • Successfully advanced dialogue among stakeholders concerning the California Biomonitoring Program (SB 1379), monitoring presence and concentration of chemicals in California

For The Record

  • 2002 - Research confirms BCA's long-standing concerns about hormone therapy and breast cancer risk
  • 1998 - BCA opposes use of tamoxifen for reduction of risk of breast cancer in healthy women
  • 1998 - BCA successfully calls for release of data showing high dose chemotherapy/bone marrow transplant does not work for breast cancer patients